221 related articles for article (PubMed ID: 36184683)
1. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer.
Monteran L; Ershaid N; Doron H; Zait Y; Scharff Y; Ben-Yosef S; Avivi C; Barshack I; Sonnenblick A; Erez N
Nat Commun; 2022 Oct; 13(1):5797. PubMed ID: 36184683
[TBL] [Abstract][Full Text] [Related]
2. Sponge-like nano-system suppresses tumor recurrence and metastasis by restraining myeloid-derived suppressor cells-mediated immunosuppression and formation of pre-metastatic niche.
Xia C; Bai W; Deng T; Li T; Zhang L; Lu Z; Zhang Z; Li M; He Q
Acta Biomater; 2023 Mar; 158():708-724. PubMed ID: 36638937
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
4. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
5. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA-sequencing identifies anti-cancer immune phenotypes in the early lung metastatic niche during breast cancer.
Orbach SM; Brooks MD; Zhang Y; Campit SE; Bushnell GG; Decker JT; Rebernick RJ; Chandrasekaran S; Wicha MS; Jeruss JS; Shea LD
Clin Exp Metastasis; 2022 Dec; 39(6):865-881. PubMed ID: 36002598
[TBL] [Abstract][Full Text] [Related]
7. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract][Full Text] [Related]
8. Micellar nanoparticles inhibit the postoperative inflammation, recurrence and pulmonary metastasis of 4T1 breast cancer by blocking NF-κB pathway and promoting MDSCs depletion.
Lu Z; Ma L; Mei L; Ren K; Li M; Zhang L; Liu X; He Q
Int J Pharm; 2022 Nov; 628():122303. PubMed ID: 36265660
[TBL] [Abstract][Full Text] [Related]
9. C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts.
Shu C; Zha H; Long H; Wang X; Yang F; Gao J; Hu C; Zhou L; Guo B; Zhu B
J Exp Clin Cancer Res; 2020 Jan; 39(1):11. PubMed ID: 31931851
[TBL] [Abstract][Full Text] [Related]
10. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
Sonnenberg M; van der Kuip H; Haubeis S; Fritz P; Schroth W; Friedel G; Simon W; Mürdter TE; Aulitzky WE
BMC Cancer; 2008 Dec; 8():364. PubMed ID: 19077243
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
13. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
[TBL] [Abstract][Full Text] [Related]
14. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
15. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.
Bandyopadhyay A; Wang L; Agyin J; Tang Y; Lin S; Yeh IT; De K; Sun LZ
PLoS One; 2010 Apr; 5(4):e10365. PubMed ID: 20442777
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
18. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer.
Hu C; Liu X; Ran W; Meng J; Zhai Y; Zhang P; Yin Q; Yu H; Zhang Z; Li Y
Biomaterials; 2017 Nov; 144():60-72. PubMed ID: 28823844
[TBL] [Abstract][Full Text] [Related]
19. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
Ghaffari A; Hoskin V; Turashvili G; Varma S; Mewburn J; Mullins G; Greer PA; Kiefer F; Day AG; Madarnas Y; SenGupta S; Elliott BE
Breast Cancer Res; 2019 Jan; 21(1):12. PubMed ID: 30678714
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
